Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-Year follow-up of a propensity score matching comparison (the BIORESOLVE-ISR Study).
Elisabetta MoscarellaAkihito TanakaAlfonso IelasiBernardo CorteseSebastian CoscarelliMaria Carmen De AngelisDavide PirainoAzeem LatibGiulietta GrigisRenatomaria BianchiDario BuccheriPaolo CalabròMaurizio TespiliPedro Silva OrregoAntonio ColomboElisabetta MoscarellaPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2018)
At 1-year follow-up the use of BVS as ISR treatment is associated with a higher, even if not significant, DOCE rate compared with EES while a similar rate compared to DEB.